Genetic Alliance and Illumina launch a $120M Global Initiative to Increase Equity and Improve Outcomes for Families Impacted by Genetic Disease

Sharon Terry, EspeRare’s President and CEO of Genetic Alliance and Ryan Taft, PhD, Vice President, Scientific Research at Illumina, Inc. announced the creation of the iHope™ Genetic Health program aiming at providing whole-genome sequencing access (WGS) to tens of thousands of patients across the globe. This flagship program will enable clinical laboratories and care centers throughout the world to test patients impacted by rare disease and other genetic health conditions.

"Since our inception in 1986, Genetic Alliance's mission has been to realize a world in which those affected by genetic disease are diagnosed and offered interventions to alleviate their suffering," said Sharon.

“We have a moral imperative to help genetic disease patients who need a diagnosis,” said Ryan Taft. “iHope Genetic Health will change the trajectory of genomic medicine worldwide, helping patients who may have otherwise been invisible”. 

To view the press release, follow the link.

About Illumina and Genetic Alliance

Illumina is improving human health by unlocking the power of the genome. Their focus on innovation has established Illumina as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. To learn more, visit www.illumina.com

Genetic Alliance, a non-profit organization founded in 1986, is a leader in deploying high tech and high touch programs for individuals, families, and communities to transform health systems by being responsive to the real needs of people in their quest for health. For more information, visit geneticalliance.org